Botta, C., Barbieri, V., Ciliberto, D., Rossi, A., Rocco, D., Addeo, R., . . . Correale, P. (2013). Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Landes Bioscience.
Παραπομπή Chicago StyleBotta, Cirino, et al. Systemic Inflammatory Status At Baseline Predicts Bevacizumab Benefit in Advanced Non-small Cell Lung Cancer Patients. Landes Bioscience, 2013.
Παραπομπή MLABotta, Cirino, et al. Systemic Inflammatory Status At Baseline Predicts Bevacizumab Benefit in Advanced Non-small Cell Lung Cancer Patients. Landes Bioscience, 2013.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.